Funded Startups in Oxford
Among Oxford-area startups with disclosed amounts, the largest recent round is Oxford’s OrganOx at $142M (2025-02-24).
Among Oxford-area startups with disclosed amounts, the largest recent round is Oxford’s OrganOx at $142M (2025-02-24). That figure dwarfs the next-largest disclosed amounts in the same window—$60M for Wild Bioscience (2025-10-13), $50M for Grey Wolf Therapeutics (2024-05-23), and $37M for PQShield (2024-06-20)—while many other disclosed rounds cluster far lower (e.g., $18M Brainomix on 2025-03-18; $15M Dendra Systems on 2024-05-08).
The 50 rows span 2023-02-16 (Oxford VR) through 2025-11-13 (Scripta Therapeutics), and there is a dense late-period cluster: 12 entries fall between 2025-01-16 and 2025-10-13, including multiple AI and biotech financings (Scripta Therapeutics Seed $12M on 2025-11-13; Wild Bioscience Series A $60M on 2025-10-13; Brainomix Series C $18M on 2025-03-18). Sector signals lean heavily to Biotechnology/AI (each appears in 3+ entries), while classification is frequently missing: “Series Unknown” occurs 17 times and “undisclosed” amounts appear 6 times.
Most recent rounds
50 shownRelated listings
Frequently asked
What stands out in disclosed round size across this Oxford list, and is it concentrated in one company?
OrganOx’s $142M (2025-02-24) is the single largest disclosed round shown and sits well above the next-largest disclosed amounts—$60M (Wild Bioscience, 2025-10-13) and $50M (Grey Wolf Therapeutics, 2024-05-23). Most other disclosed rounds fall below these levels (e.g., $37M PQShield on 2024-06-20; $28M OXCCU on 2025-10-04).
Do these Oxford-funded deals cluster in a particular time window near the top of the list?
Yes. Twelve of the 50 rows are dated between 2025-01-16 (Hygen Energy) and 2025-10-13 (Wild Bioscience). That cluster includes multiple large biotech/AI financings such as Oxford’s OXCCU Series B $28M (2025-10-04) and OrganOx Series Unknown $142M (2025-02-24).
Is the “Oxford” geography internally consistent, or is there a same-name location outlier?
There is a clear geography outlier: Apothecary & Co is listed as Oxford, Michigan, United States (Series Unknown, $10K on 2023-08-23), while the rest of the entries shown are Oxford, United Kingdom / Oxfordshire, United Kingdom.
How complete are stage and amount disclosures, and does that affect how you should interpret comparisons?
Stage visibility is limited: “Series Unknown” appears 17 times, and amounts are “undisclosed” 6 times (e.g., Salience Labs on 2025-10-03; GaitQ on 2024-04-11; Quantum Dice on 2024-02-15). As a result, size and stage comparisons are most reliable among disclosed amounts with explicit stages (e.g., Wild Bioscience Series A $60M vs. SQ-level entries marked undisclosed).
Which thematic areas appear often enough to treat this as a real cluster rather than isolated listings?
Biotechnology and AI both show up in 3+ entries. Examples for Biotechnology include Wild Bioscience ($60M, 2025-10-13), Oxford Endovascular ($10M, 2024-05-20), and Genomics ($45M, 2024-01-08); examples for AI include Scripta Therapeutics (Seed $12M, 2025-11-13), Brainomix (Series C $18M, 2025-03-18), and Diffblue (Series Unknown $6M, 2024-10-30).
Are any very small disclosed rounds clear outliers within the disclosed set?
Among disclosed amounts, the smallest is PD Buddy at $30K (Pre-Seed on 2024-05-01). That $30K entry is an order of magnitude below many nearby disclosed rounds in the same period (e.g., Oxford Cannabinoid Technologies $720K on 2024-02-02 and StreetDrone $210K on 2023-05-11).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.